ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Altimmune, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.23+0.03 (+1.36%)
Close on Oct 19, 2026
- Market cap
- $413.54M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
77.9%
152M of 195M shares
Institutional holders
210
58 new, 18 sold out
Net institutional buying
82M
In Q2 2026
Insider trades, 12 months
11 buys · 0 sales
Net bought $370.12K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| State Street Corporation | 7,145,550 | 5.50% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 6,133,427 | 7.60% | 13G (passive) amendment | Jun 30, 2025 |
| Chen Yu | 20,000,000 | 9.80% | 13G (passive) | Apr 24, 2026 |
| David Kroin | 19,417,221 | 9.99% | 13G (passive) | Apr 23, 2026 |
| Halvorsen Ole Andreas | 13,400,000 | 6.70% | 13G (passive) | Apr 24, 2026 |
| Rajeev Shah | 13,000,000 | 6.50% | 13G (passive) | Apr 24, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,385,284 | 10.48% | $61.97M | +7,590,007 | 0.00% |
| Deep Track Capital, LP | 19,250,000 | 9.90% | $58.52M | New | 0.85% |
| State Street Corp | 12,098,540 | 6.22% | $36.78M | +4,952,990 | 0.00% |
| TCG Crossover Management, LLC | 10,000,000 | 5.14% | $30.40M | New | 0.73% |
| Vanguard Capital Management LLC | 8,177,752 | 4.20% | $24.86M | +2,519,703 | 0.00% |
| Vanguard Portfolio Management LLC | 7,330,265 | 3.77% | $22.28M | +1,948,263 | 0.00% |
| Marshall Wace, Llp | 6,841,055 | 3.52% | $20.80M | +2,823,154 | 0.02% |
| Viking Global Investors LP | 6,700,000 | 3.44% | $20.37M | New | 0.06% |
| Ra Capital Management, L.P. | 6,500,000 | 3.34% | $19.76M | New | 0.17% |
| Geode Capital Management, LLC | 5,011,314 | 2.58% | $15.24M | +1,904,218 | 0.00% |
| Woodline Partners LP | 3,400,312 | 1.75% | $10.34M | New | 0.03% |
| Millennium Management LLC | 3,309,122 | 1.70% | $10.06M | +50,931 | 0.00% |
| Nantahala Capital Management, LLC | 3,000,000 | 1.54% | $9.12M | New | 0.15% |
| Trails Edge Capital Partners, LP | 2,660,000 | 1.37% | $8.09M | New | 1.28% |
| Nuveen, LLC | 2,405,354 | 1.24% | $7.31M | +70,753 | 0.00% |
| Two Sigma Investments, LP | 2,381,142 | 1.22% | $7.24M | −97,758 | 0.01% |
| Goldman Sachs Group Inc | 2,214,450 | 1.14% | $6.73M | +863,801 | 0.00% |
| Great Point Partners LLC | 1,741,232 | 0.90% | $5.29M | New | 1.00% |
| Northern Trust Corp | 1,599,226 | 0.82% | $4.86M | +602,505 | 0.00% |
| Weiss Asset Management LP | 1,530,803 | 0.79% | $4.65M | New | 0.05% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 210 | 152M | 77.9% | 58 / 87 | 33 / 18 | 88M | 6M |
| Q1 2026 | 173 | 69M | 35.7% | 30 / 81 | 35 / 35 | 34M | 10M |
| Q4 2025 | 183 | 55M | 28.4% | 49 / 73 | 29 / 21 | 18M | 4M |
| Q3 2025 | 158 | 42M | 21.4% | 23 / 57 | 48 / 42 | 10M | 6M |
| Q2 2025 | 180 | 38M | 19.4% | 38 / 71 | 41 / 34 | 8M | 9M |
| Q1 2025 | 177 | 38M | 19.6% | 27 / 54 | 52 / 29 | 6M | 8M |
| Q4 2024 | 182 | 41M | 20.9% | 38 / 64 | 45 / 23 | 5M | 4M |
| Q3 2024 | 169 | 40M | 20.4% | 22 / 59 | 46 / 25 | 9M | 7M |
| Q2 2024 | 173 | 43M | 22.0% | 45 / 53 | 47 / 40 | 13M | 19M |
| Q1 2024 | 171 | 49M | 25.2% | 59 / 51 | 38 / 30 | 24M | 10M |
| Q4 2023 | 143 | 35M | 17.8% | 56 / 41 | 24 / 25 | 16M | 12M |
| Q3 2023 | 112 | 30M | 15.6% | 16 / 27 | 40 / 23 | 2M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ALT | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 8,096,724 | 4.16% | $24.61M | 0.23% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 5,748,771 | 2.96% | $17.48M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 5,161,850 | 2.65% | $15.69M | 0.02% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 2,519,635 | 1.30% | $7.66M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,236,217 | 1.15% | $6.80M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,173,494 | 1.12% | $6.17M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 1,869,684 | 0.96% | $5.68M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,295,713 | 0.67% | $3.94M | 0.04% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,213,513 | 0.62% | $3.45M | 0.02% | Jul 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 1,045,359 | 0.54% | $3.19M | 0.06% | May 29, 2026 |
| Fidelity Extended Market Index Fund | 988,478 | 0.51% | $3.01M | 0.01% | May 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 867,177 | 0.45% | $2.64M | 0.08% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 670,084 | 0.34% | $2.04M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 668,001 | 0.34% | $2.03M | 0.13% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 638,025 | 0.33% | $1.94M | 0.03% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jerome Benedict Durso | President and CEO, Director | 62,500 | 0.03% | Aug 13, 2026 |
| Linda M. Richardson | Chief Commercial Officer | 24,000 | 0.01% | Sep 17, 2026 |
| M. Scot Roberts | Chief Scientific Officer | 113,714 | 0.06% | Aug 3, 2026 |
| Gregory L. Weaver | Chief Financial Officer | 39,831 | 0.02% | Aug 3, 2026 |
| Raymond M. Jordt | Chief Business Officer | 70,107 | 0.04% | Feb 2, 2026 |
| Christophe Arbet-Engels | Chief Medical Officer | – | – | Oct 3, 2025 |
| Matthew Scott Harris | Chief Medical Officer | 83,874 | 0.04% | Aug 4, 2025 |
| Klaus Schafer | Director | 8,960 | 0.00% | May 1, 2026 |
| Philip Hodges | Director | 26,579 | 0.01% | May 1, 2026 |
| Wayne Pisano | Director | 13,498 | 0.01% | May 1, 2026 |
| Mitchel Sayare | Director | 59,013 | 0.03% | May 1, 2026 |
| Catherine A. Sohn | Director | 1,500 | 0.00% | May 1, 2026 |
| John Gill | Director | 21,700 | 0.01% | May 1, 2026 |
| Diane Jorkasky | Director | 527 | 0.00% | May 1, 2026 |
| Teri L. Lawver | Director | – | – | May 1, 2026 |
| Vipin K. Garg | Director | 424,519 | 0.22% | Feb 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Linda M. Richardson Chief Commercial Officer | Sep 16, 2026 | Option exercise | +24,000 | – | – | 24,000 |
| Linda M. Richardson Chief Commercial Officer | Sep 16, 2026 | Tax withholding | −6,826 | $3.24 | $22.12K | 17,174 |
| Jerome Benedict Durso President and CEO, Director | Aug 13, 2026 | Buy | +15,000 | $2.95 | $44.25K | 62,500 |
| Gregory L. Weaver Chief Financial Officer | Jul 31, 2026 | Award | +1,753 | $2.41 | $4.22K | 39,831 |
| M. Scot Roberts Chief Scientific Officer | Jul 31, 2026 | Award | +875 | $2.41 | $2.11K | 113,699 |
| John Gill Director | Apr 6, 2026 | Buy | +9,200 | $3.41 | $31.37K | 21,700 |
| Gregory L. Weaver Chief Financial Officer | Apr 1, 2026 | Buy | +10,000 | $3.15 | $31.50K | 38,078 |
| Jerome Benedict Durso President and CEO, Director | Apr 1, 2026 | Buy | +15,000 | $3.14 | $47.10K | 47,500 |
| Gregory L. Weaver Chief Financial Officer | Mar 6, 2026 | Buy | +5,000 | $3.54 | $17.70K | 28,078 |
| Jerome Benedict Durso President and CEO, Director | Mar 6, 2026 | Buy | +20,000 | $3.54 | $70.80K | 32,500 |
| M. Scot Roberts Chief Scientific Officer | Feb 2, 2026 | Tax withholding | −2,329 | $5.55 | $12.93K | 112,824 |
| M. Scot Roberts Chief Scientific Officer | Feb 2, 2026 | Option exercise | +7,775 | – | – | 115,153 |
| M. Scot Roberts Chief Scientific Officer | Jan 31, 2026 | Award | +5,567 | $3.07 | $17.09K | 107,378 |
| Raymond M. Jordt Chief Business Officer | Jan 31, 2026 | Award | +4,571 | $3.07 | $14.03K | 70,107 |
| Vipin K. Garg Director | Jan 31, 2026 | Award | +6,926 | $3.07 | $21.26K | 424,519 |
| M. Scot Roberts Chief Scientific Officer | Jan 30, 2026 | Tax withholding | −2,859 | $5.60 | $16.01K | 101,811 |
| M. Scot Roberts Chief Scientific Officer | Jan 30, 2026 | Option exercise | +9,275 | – | – | 104,670 |
| Vipin K. Garg Director | Jan 30, 2026 | Option exercise | +26,775 | – | – | 429,225 |
| Vipin K. Garg Director | Jan 30, 2026 | Tax withholding | −11,632 | $5.60 | $65.14K | 417,593 |
| M. Scot Roberts Chief Scientific Officer | Jan 27, 2026 | Option exercise | +15,850 | – | – | 100,143 |
| M. Scot Roberts Chief Scientific Officer | Jan 27, 2026 | Tax withholding | −4,748 | $6.18 | $29.34K | 95,395 |
| Raymond M. Jordt Chief Business Officer | Jan 27, 2026 | Tax withholding | −4,229 | $6.18 | $26.14K | 65,536 |
| Raymond M. Jordt Chief Business Officer | Jan 27, 2026 | Option exercise | +15,850 | – | – | 69,765 |
| Vipin K. Garg Director | Jan 27, 2026 | Tax withholding | −17,898 | $6.18 | $110.61K | 402,450 |
| Vipin K. Garg Director | Jan 27, 2026 | Option exercise | +41,200 | – | – | 420,348 |
| M. Scot Roberts Chief Scientific Officer | Jan 25, 2026 | Tax withholding | −4,373 | $5.50 | $24.05K | 84,293 |
| M. Scot Roberts Chief Scientific Officer | Jan 25, 2026 | Option exercise | +14,600 | – | – | 88,666 |
| Vipin K. Garg Director | Jan 25, 2026 | Tax withholding | −17,984 | $5.50 | $98.91K | 379,148 |
| Vipin K. Garg Director | Jan 25, 2026 | Option exercise | +42,050 | – | – | 397,132 |
| Raymond M. Jordt Chief Business Officer | Jan 25, 2026 | Tax withholding | −3,855 | $5.50 | $21.20K | 53,915 |
| Raymond M. Jordt Chief Business Officer | Jan 25, 2026 | Option exercise | +14,600 | – | – | 57,770 |
| Wayne Pisano Director | Jan 8, 2026 | Buy | +5,000 | $4.08 | $20.40K | 13,498 |
| Catherine A. Sohn Director | Jan 5, 2026 | Buy | +500 | $4.24 | $2.12K | 1,500 |
| Raymond M. Jordt Chief Business Officer | Jan 1, 2026 | Tax withholding | −2,475 | $3.61 | $8.93K | 43,170 |
| Raymond M. Jordt Chief Business Officer | Jan 1, 2026 | Option exercise | +9,375 | – | – | 45,645 |
| Diane Jorkasky Director | Dec 29, 2025 | Buy | +527 | $3.80 | $2.00K | 527 |
| John Gill Director | Dec 23, 2025 | Buy | +12,500 | $4.10 | $51.25K | 12,500 |
| Jerome Benedict Durso Director | Dec 22, 2025 | Buy | +12,500 | $4.13 | $51.63K | 12,500 |
| Gregory L. Weaver Chief Financial Officer | Nov 11, 2025 | Option exercise | +18,750 | – | – | 28,750 |
| Gregory L. Weaver Chief Financial Officer | Nov 11, 2025 | Tax withholding | −5,672 | $4.28 | $24.28K | 23,078 |
| M. Scot Roberts Chief Scientific Officer | Jul 31, 2025 | Award | +846 | $3.14 | $2.66K | 74,066 |
| Matthew Scott Harris Chief Medical Officer | Jul 31, 2025 | Award | +2,018 | $3.14 | $6.34K | 16,087 |
| Raymond M. Jordt Chief Business Officer | Jul 31, 2025 | Award | +1,368 | $3.14 | $4.30K | 36,270 |
| Catherine A. Sohn Director | Mar 17, 2025 | Buy | +1,000 | $5.78 | $5.78K | 1,000 |
| Gregory L. Weaver Chief Financial Officer | Mar 13, 2025 | Buy | +10,000 | $5.20 | $52.00K | 10,000 |
| Matthew Scott Harris Chief Medical Officer | Mar 7, 2025 | Gift | −67,787 | – | – | 14,069 |
| Vipin K. Garg President and CEO, Director | Feb 2, 2025 | Option exercise | +18,950 | – | – | 363,364 |
| Vipin K. Garg President and CEO, Director | Feb 2, 2025 | Tax withholding | −8,282 | $6.64 | $54.99K | 355,082 |
| M. Scot Roberts Chief Scientific Officer | Feb 2, 2025 | Option exercise | +7,775 | – | – | 75,536 |
| M. Scot Roberts Chief Scientific Officer | Feb 2, 2025 | Tax withholding | −2,316 | $6.64 | $15.38K | 73,220 |
| Matthew Scott Harris Chief Medical Officer | Feb 2, 2025 | Option exercise | +7,775 | – | – | 84,564 |
| Matthew Scott Harris Chief Medical Officer | Feb 2, 2025 | Tax withholding | −2,708 | $6.64 | $17.98K | 81,856 |
| Vipin K. Garg President and CEO, Director | Feb 1, 2025 | Option exercise | +16,545 | – | – | 351,645 |
| Vipin K. Garg President and CEO, Director | Feb 1, 2025 | Tax withholding | −7,231 | $6.64 | $48.01K | 344,414 |
| M. Scot Roberts Chief Scientific Officer | Feb 1, 2025 | Option exercise | +6,166 | – | – | 69,562 |
| M. Scot Roberts Chief Scientific Officer | Feb 1, 2025 | Tax withholding | −1,801 | $6.64 | $11.96K | 67,761 |
| Matthew Scott Harris Chief Medical Officer | Feb 1, 2025 | Tax withholding | −2,109 | $6.64 | $14.00K | 76,789 |
| Matthew Scott Harris Chief Medical Officer | Feb 1, 2025 | Option exercise | +6,166 | – | – | 78,898 |
| Vipin K. Garg President and CEO, Director | Jan 31, 2025 | Award | +4,105 | $5.18 | $21.26K | 335,100 |
| M. Scot Roberts Chief Scientific Officer | Jan 31, 2025 | Award | +3,184 | $5.18 | $16.49K | 63,396 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.